Covance Appoints Dr. Jeffrey J. Stoddard to Lead Risk Management and Postmarketing Programs
June 19, 2006
Princeton, New Jersey, June 19, 2006 - Covance (NYSE: CVD) today announced the appointment of Jeffrey J. Stoddard, M.D. as Covance's Vice President, Medical and Scientific Affairs, Risk Management and Postmarketing Programs. In this capacity, Dr. Stoddard will lead Covance's risk management and postmarketing business and have responsibility for providing scientific and technical leadership in these important areas.
This move strengthens Covance's leadership team, in light of the increasing regulatory and public scrutiny around biopharmaceutical product safety and the ongoing need to document benefit in diverse populations. It also improves the company's ability to help biopharmaceutical firms proactively address signal detection, risk minimization, pharmacovigilance and benefit characterization from the earliest stages of development, through to patient access and approved products.
"Dr. Stoddard's broad background of medical practice, his close links with leading academic institutions and government agencies, and his work on vaccines in vulnerable populations make him the ideal person to meet the industry's growing need for leadership in risk management and benefit characterization," said Dr. Larry Meinert, Covance's Senior Vice President, Medical and Scientific Affairs. "Working within a scientific and operational community that spans the drug development continuum from early, to late-stage and commercialization, Dr. Stoddard and his team will be able to help Covance clients build risk management into the core of their development processes."
"Covance is uniquely positioned to meet pharmaceutical manufacturers' needs from preclinical testing through marketed product," said Stoddard. "The ability to look at data throughout the development continuum from various phases and incorporate it into research design can significantly increase public safety and help practitioners optimally use pharmaceutical products."
Dr. Stoddard will lead the Covance Risk Management Expert Panel, an internal team of scientific experts in preclinical and clinical research, regulatory affairs, drug safety, epidemiology and commercialization. This panel provides clients with comprehensive risk management consulting from preclinical testing through commercialization.
Prior to joining Covance, Dr. Stoddard was Senior Director, Medical Affairs at MedImmune, a biopharmaceutical company, and also a physician researcher for the Center for Studying Health System Change. Dr. Stoddard held numerous staff appointments practicing medicine. His areas of research focus include vaccines, preventative medicine and pediatrics.
Company Name: Covance
Phone: 8002682623
URL: www.covance.com
Contact Name: Ron Lee
E-mail: netpr@covance.com
